[Federal Register Volume 61, Number 197 (Wednesday, October 9, 1996)]
[Notices]
[Pages 52949-52950]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-25878]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 96M-0358]
EDAP Technomed Group (U.S.A.), Inc.; Premarket Approval of
ProstatronTM
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing its
approval of the application by the EDAP Technomed Group (U.S.A), Inc.,
Cambridge, MA, for premarket approval, under the Federal Food, Drug,
and Cosmetic Act (the act), of the ProstatronTM. After reviewing
the recommendation of the Gastroenterology and Urology Devices Panel of
the Medical Devices Advisory Committee, FDA's Center for Devices and
Radiological Health (CDRH) notified the applicant, by letter of May 3,
1996, of the approval of the application.
DATES: Petitions for administrative review by November 8, 1996.
ADDRESSES: Written requests for copies of the summary of safety and
effectiveness data and petitions for administrative review to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: John H. Baxley, Center for Devices and
Radiological Health (HFZ-470), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-594-2194.
SUPPLEMENTARY INFORMATION: On April 17, 1995, the EDAP Technomed Group
[[Page 52950]]
(U.S.A.), Inc., Cambridge, MA 02139, submitted to CDRH an application
for premarket approval of the ProstatronTM. The device is a
transurethral microwave thermal therapy system and is indicated as a
nonsurgical treatment alternative to transurethral resection of the
prostate (TURP) for the treatment of symptomatic benign prostatic
hyperplasia (BPH). The ProstatronTM is indicated for patients with
prostatic lengths of 35 to 50 millimeters. It is intended that the
ProstatronTM deliver a complete thermal therapy treatment during a
single treatment session.
On October 20, 1995, the Gastroenterology and Urology Devices Panel
of the Medical Devices Advisory Committee, an FDA advisory committee,
reviewed and recommended approval of the application. On May 3, 1996,
CDRH approved the application by a letter to the applicant from the
Director of the Office of Device Evaluation, CDRH.
A summary of the safety and effectiveness data on which CDRH based
its approval is on file in the Dockets Management Branch (address
above) and is available from that office upon written request. Requests
should be identified with the name of the device and the docket number
found in brackets in the heading of this document.
Opportunity for Administrative Review
Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any
interested person to petition, under section 515(g) of the act, for
administrative review of CDRH's decision to approve this application. A
petitioner may request either a formal hearing under part 12 (21 CFR
part 12) of FDA's administrative practices and procedures regulations
or a review of the application and CDRH's action by an independent
advisory committee of experts. A petition is to be in the form of a
petition for reconsideration under Sec. 10.33(b) (21 CFR 10.33(b)). A
petitioner shall identify the form of review requested (hearing or
independent advisory committee) and shall submit with the petition
supporting data and information showing that there is a genuine and
substantial issue of material fact for resolution through
administrative review. After reviewing the petition, FDA will decide
whether to grant or deny the petition and will publish a notice of its
decision in the Federal Register. If FDA grants the petition, the
notice will state the issue to be reviewed, the form of review to be
used, the persons who may participate in the review, the time and place
where the review will occur, and other details.
Petitioners may, at any time on or before November 8, 1996, file
with the Dockets Management Branch (address above) two copies of each
petition and supporting data and information, identified with the name
of the device and the docket number found in brackets in the heading of
this document. Received petitions may be seen in the office above
between 9 a.m. and 4 p.m., Monday through Friday.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h)) and under
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10)
and redelegated to the Director, Center for Devices and Radiological
Health (21 CFR 5.53).
Dated: September 20, 1996.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and
Radiological Health.
[FR Doc. 96-25878 Filed 10-8-96; 8:45 am]
BILLING CODE 4160-01-F
